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Acylation stimulating protein (ASP) is a potent stim-
ulator of triglyceride synthesis in adipocytes. In the
present study, we have examined the effect of an ASP
functional knockout (ASP(2/2)) on lipid metabolism in
male mice. In both young (14 weeks) and older (26
weeks) mice there were marked delays in postprandial
triglyceride clearance (80% increase at 14 weeks and
120% increase at 26 weeks versus wild type (1/1)). Post-
prandial nonesterified fatty acids were also increased in
ASP(2/2) mice versus ASP(1/1) mice by 37% (low fat 10%
Kcal) and by 73% (high fat 40% Kcal) diets, although
there were no differences in fasting lipid levels. The
ASP(2/2) mice had moderately increased energy intake
(16% 6 2% p < 0.0001) and reduced feed efficiency (33%
increase in calories/g of body weight gained on low fat
diet) versus wild type. The ASP(2/2) mice also had mod-
est changes in insulin/glucose metabolism (30% to 40%
decrease in insulinzglucose product), implying in-
creased insulin sensitivity. As well, there were de-
creases in leptin (29% shift in leptin to body weight
ratio) and up to a 26% decrease in specific adipose tissue
depots versus the wild type mice on both low fat and
high fat diets. These results demonstrate that ASP plays
an important role in adipose tissue metabolism and fat
partitioning.
Acylation stimulating protein (ASP)1 is a 76-amino acid pro-
tein identical to C3adesArg, a cleavage product of complement
C3. Extensive in vitro data demonstrate an ASP effect on fatty
acid esterification in human and murine adipocytes and prea-
dipocytes (1–3) as well as human fibroblasts (4–6). Recently, it
has been demonstrated that ASP also inhibits hormone-sensi-
tive lipase through an effect on phosphodiesterase 3 (PDE3) (7).
ASP also stimulates glucose transport in human and murine
adipocytes and preadipocytes (2, 8) as well as human fibro-
blasts (4) and differentiated rat muscle cells (9). This effect on
glucose transport is consequent to translocation of Glut 1 or
Glut 3 or Glut 4 (depending on the particular cell). The effects
of ASP are likely mediated through interaction with a specific
cell surface receptor that demonstrates high affinity binding
and tissue-specific distribution (for a review on ASP see Ref. 3).
Adipose tissue mass is determined by the rate of the opposing
reactions, triglyceride synthesis, and lipolysis. Since ASP stim-
ulates triglyceride synthesis and inhibits lipolysis and does so
independently and additively with insulin (4, 7–9), ASP has the
potential to profoundly influence adipose tissue metabolism.
ASP is produced through the interaction of complement C3,
factor B, and adipsin (10, 11), and all three factors are ex-
pressed and secreted by human and murine adipocytes in a
differentiation-dependent manner (1, 12, 13). The production of
ASP by cultured adipocytes is stimulated by chylomicrons (14,
15). Although there is substantial in vitro data on ASP produc-
tion, there have been far less in vivo studies to date on ASP. In
the general circulation there appears to be a slight decrease in
ASP over time following a fat load (16). However, generation of
ASP does increase postprandially locally across an arterial-
venous adipose tissue gradient (17) but not across a muscle
gradient.2 Our hypothesis is that ASP increases the efficiency
of dietary energy storage through its cellular effects on lipid
and glucose tissue storage.
The development of C3 knockout mice (18) allowed us the
opportunity to examine the effects of an obligatory ASP knock-
out (since the precursor to ASP, C3, is absent in mouse plasma)
on postprandial metabolism. In our first study on young (8–10
weeks old) male and female mice, we demonstrated increased
postprandial triglyceride (TG) in the ASP(2/2) mice in the
absence of any change in fasting TG (19). These effects were
more pronounced in the males than in the females. Conversely,
administration of ASP to ASP(2/2) mice (19) or to wild type
Black6 mice (20) enhanced the clearance of triglyceride and
decreased postprandial lipemia.
The aim of the present study was to examine the ASP(2/2)
phenotype in more detail in a longitudinal study with different
diets (10% low fat and 40% high fat). We postulated that the
wild type ASP(1/1) mice on the high fat diet would mimic the
knockout ASP(2/2) phenotype and that the high fat diet would
amplify the effects of the ASP(2/2) phenotype.
MATERIALS AND METHODS
Ethics—All experimental protocols were approved by the Royal Vic-
toria Hospital Animal Ethics committee and were in accordance with
the guidelines set out by the Canadian Committee on Animal Care.
Mice—Dr. H. Colten and Dr. R. H. Wetsel kindly provided the knock-
out and wild type mice for breeding. Development of the complement C3
* This study was supported by grants from National Science and
Engineering Council of Canada (to K. C.) and Servier Pharmaceuticals
(to A. D. S.). The costs of publication of this article were defrayed in part
by the payment of page charges. This article must therefore be hereby
marked “advertisement” in accordance with 18 U.S.C. Section 1734
solely to indicate this fact.
‡ A recipient of the Colonel Renouf Fellowship (Royal Victoria Hos-
pital Research Institute).
¶ Supported by National Institutes of Health Grants DK-35747 and
DK-50129 and grants from the U. S. Department of Agriculture and the
American Diabetes Association.
i A research scholar of the Fonds de Recherche en Sante du Quebec.
To whom correspondence should be addressed: Cardiology, H 7.30,
Royal Victoria Hospital, 687 Pine Ave. West, Montreal, Quebec, Can-
ada, H3A 1A1. Tel.: 514-842-1231 (ext. 5426); Fax: 514-982-0686; E-
mail: mdkc@musica.mcgill.ca.
1 The abbreviations used are: ASP, acylation stimulating protein;
ANOVA, analysis of variance; TG, triglyceride; LF, low fat; HF, high
fat; NEFA, plasma non-esterified fatty acids; AUC, area under the
curve; CHOL, cholesterol; LDL, low density lipoproteins; VLDL, very
LDL; GTT, glucose tolerance test; HDL, high density lipoproteins; LPL,
lipoprotein lipase. 2 A. D. Sniderman and K. Cianflone, unpublished observations.
THE JOURNAL OF BIOLOGICAL CHEMISTRY Vol. 274, No. 51, Issue of December 17, pp. 36219–36225, 1999
© 1999 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in U.S.A.
This paper is available on line at http://www.jbc.org 36219
knockout has been described elsewhere in detail (18, 21). The mice were
of (129Sv 3 C57Bl/6) strain, and heterozygous mating produced the
littermates (wild type ASP(1/1) and knockout ASP(2/2)) used for the
present experiments. Mice were housed in sterile barrier facilities with
equal day/night periods. In all cases, littermates were used to random-
ize genetic variation.
Genotyping—For genotyping, tail DNA was extracted, and polymer-
ase chain reaction was performed. Polymerase chain reaction was per-
formed using 800 nM each of the following primers: C3 sense, CTT AAC
TGT CCC ACT GCC AAG AAA CCG TCC CAG ATC; C3 antisense, CTC
TGG TCC CTC CCT GTT CCT GCA CCA GGG ACT GCC CAA AAT
TTC GCA AC; neomycin sense, ATC GCA TCG AGC GAG CAC GTA
CTC GGA; neomycin antisense, AGC TCT TCA GCA ATA TCA CGG
CTA GCC. Polymerase chain reaction conditions were 30 cycles at 94 °C
for 1 min, 67 °C for 2 min, and 72 °C for 3 min. Products were separated
by electrophoresis on a 7% polyacrylamide gel and visualized with
ethidium bromide staining.
Diet, Feeding, and Weighing—ASP(1/1) and ASP(2/2) male mice
were weighed once weekly from weaning at 4 weeks of age. At 8 weeks,
the mice were housed individually and allowed to acclimatize for 2
weeks. At 10 weeks of age, the mice were placed on a pelleted low fat
diet (LF) consisting of 19.3% protein, 67.3% carbohydrate, and 4.3% fat
(w/w) or high fat diet (HF) consisting of 22.9% protein, 45.8% carbohy-
drate, and 20.3% fat w/w modified from Van Heek et al. (22) and
obtained from Research Diets, Inc. (New Brunswick, NJ) (Diets D12477
and D12478, respectively). The diets contained 10% Kcal (LF) and 40%
Kcal (HF) energy from fat, with a 1:1:1 ratio of saturated:monounsat-
urated: polyunsaturated fats and were stored at 4 °C. Carbohydrate
was in the form of cornstarch rather than sucrose (70% LF and 40% HF
Kcal). The vitamin and mineral content conformed with the AIN (Amer-
ican Institutes of Nutrition) guidelines. The food was weighed 3 times
weekly over a period of 16 weeks, and food intake was determined over
the time period of 10 to 26 weeks of age. After 1 month on the diet, a fat
load was performed, and 2 weeks later a fasting blood samples was
taken. The same treatment was repeated at 4 months on the diet (26
and 28 weeks of age). On a subset of mice, a glucose tolerance test was
performed at 30 weeks of age, and mice were sacrificed at 32 weeks or
48 weeks. Mice were anesthetized (0.01 ml/10 g of body weight intra-
muscularly) with a mixture composed of 5 ml of ketamine (100 mg/ml),
2.5 ml of xylazine (20 mg/ml), 1 ml of acepromazine (10 mg/ml), and 1.5
ml of sterile saline. Blood was drawn from the tail (0.5 ml), and the mice
were sacrificed by cervical dislocation. Tissues were dissected, weighed,
and frozen in liquid nitrogen. Four adipose tissues depots were col-
lected: inguinal, pectoral and suprascapular together, gonadal fat up to
the apex of the ovary, and perirenal adipose tissue with the adrenal
gland removed. Additional tissues collected were heart, liver, intras-
capular and scapular brown adipose tissue, both kidneys, and quadri-
ceps muscles with all visible fat removed.
Plasma Assays—Blood was collected by tail bleeding into EDTA-
containing tubes by tail bleeding as described previously (19, 20) from
mice fasted overnight (16 h) with water ad libitum at 10, 16, 28, and 32
weeks of age. Blood was separated by centrifugation, and the plasma
was stored at 280 °C. Leptin was measured using a mouse leptin
radioimmunoassay (Linco Inc. St Charles, MO) as described previously
(23). Fasting insulin was measured using a rat insulin radioimmuno-
assay kit that had 100% cross-reactivity to mouse insulin (as described
by the manufacturer, Linco Inc). Glucose was measured using a Trinder
glucose kit (Sigma). Plasma free fatty acids (NEFA), cholesterol, and
triglycerides were measured using colorimetric enzymatic kits (Roche
Molecular Biochemicals).
Fat Load—After an overnight fast (16 h), 400 ml of olive oil (followed
by 100 ml of air) was given by gastric gavage using a feeding tube (1-cm
curved ball tipped feeding needle 20), according to standard procedures
as published previously (19, 20) and similar to previously published
methods (24–27). Blood (40 ml) was collected by tail bleeding at 0, 1, 2,
3, 4, and 6 h.
Glucose Load—For glucose tolerance tests, mice were fasted over-
night for 16 h with water ad libitum. Basal blood was taken (80 ml), and
mice were injected intraperitoneally with a sterile D-glucose solution in
saline, 2 mg/g of body weight from a stock solution of 200 mg/ml (0.010
ml/g of body weight). Blood was collected at 15, 30, 60, 90, and 120 min.
Insulin and glucose were measured 0, 30, 60, and 120 min (80 ml
collected), and glucose only was measured at 15 and 90 min (20 ml
collected).
Statistical Analyses—Results are presented as the mean 6 S.E. The
two groups were compared by repeated measures of two-way ANOVA
followed by Bonferroni post-test or by the area under the curve (AUC)
(for time course data), t test, ANOVA (fasting data), or Pearson corre-
lation using computer-assisted analysis (Sigma Stat, Jandel Scientific,
San Rafael, CA and Prism, GraphPad San Diego, CA).
RESULTS
Mice were examined at three time points, at 10 weeks of age,
14 weeks of age (after 1 month on a low fat or a high fat diet),
and again at 26 weeks of age (after a total of 4 months on a low
fat or high fat diet). The diets contained a fixed amount of
protein (20%), and as the fat content was increased (10% to 40%
of energy), the carbohydrate contribution was proportionally
reduced (70 to 40% of energy). Basal fasting lipids for male wild
type ASP(1/1) and male knockout ASP(2/2) mice are shown
in Table I. Overall there was no change in plasma TG between
the wild type ASP(1/1) and ASP(2/2) mice, nor was there any
effect of diet or age. Plasma cholesterol (CHOL) on the other
hand increased with age and also increased on a high fat diet,
as has been reported elsewhere (28–30). Although there ap-
peared to be a trend toward increased plasma CHOL in the
(2/2) mice, especially in the older mice, the differences were
not significant and were due primarily to increases in HDL
CHOL in the ASP(2/2) knockout with no change in VLDL 1
LDL CHOL (results not shown). Plasma NEFA decreased with
age as seen previously (31), although there was no effect of the
high fat diet on these parameters. Although young ASP(2/2)
mice (10 weeks old) had higher plasma NEFA and slightly
increased VLDL 1 LDL CHOL versus wild type, as shown
previously (19), this was not apparent as the mice aged.
We have previously demonstrated that young male
ASP(2/2) mice (8–10 weeks old) demonstrate small but signif-
icant delays in TG clearance following a fat load with a 52%
increase in TG AUC (19). As shown in Fig. 1, at 14 weeks of age
(on a low fat diet) there is a substantial difference in postpran-
dial TG in the ASP(2/2) as compared with ASP(1/1) (893 6
TABLE I
Fasting plasma lipids in ASP (2/2) and ASP (1/1) mice
Fasting samples were obtained from ASP (2/2) and (1/1) mice at the indicated ages (sample size indicated for each group). Values are expressed
as the average 6 S.E.
Mice Type Sample size Triglyceride Cholesterol NEFA
mM mM mM
10 weeks (1/1) 7 58.5 6 5.1 63.0 6 4.6 0.87 6 0.18
(2/2) 12 72.6 6 11.7 67.0 6 4.3 1.97 6 0.52a
14 weeks, LF (1/1) 9 51.1 6 8.9 91.8 6 14.4 0.54 6 0.09
(2/2) 7 53.2 6 6.7 74.0 6 5.1 0.48 6 0.05
14 weeks, HF (1/1) 9 70.6 6 7.3 95.8 6 7.8 0.47 6 0.10
(2/2) 8 67.0 6 5.6 105.6 6 10.4 0.61 6 0.12
26 weeks, LF (1/1) 9 46.1 6 6.0 92.1 6 6.2 0.35 6 0.05
(2/2) 7 57.6 6 4.8 108.2 6 13.9 0.41 6 0.07
26 weeks, HF (1/1) 10 65.6 6 2.6 127.7 6 7.4 0.29 6 0.02
(2/2) 7 69.9 6 7.5 148.3 6 20.4 0.38 6 0.07
a p , 0.05 for (2/2) vs. (1/1) at the indicated age.
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279 (2/2) versus 497 6 90 (1/1) AUC mg/dlzh, an 80% in-
crease, p , 0.02). There is no difference in the NEFA postpran-
dial profile between the two groups (Fig. 1, right panel). The
postprandial TG curves after 1 month on the HF diet are shown
in Fig. 2. The high fat diet results in a delay in postprandial TG
clearance in the ASP(1/1) mice such that the TG AUC in-
creases by 65% versus the ASP(1/1) control on LF (820 6 149
mg/dlzh, p , 0.01). The postprandial curve of the ASP(2/2)
mice slightly increased as compared with the ASP(2/2) on LF
diet (1094 6 242 mg/dlzh AUC). However, in the ASP(2/2) mice
on HF there was also a pronounced increase in the postprandial
plasma NEFA (2.5 fold) that did not occur in the ASP(1/1)
mice on the high fat diet (Fig. 2, right panel).
After a total of 4 months on the respective diets, we reexam-
ined postprandial responses in the mice. The results for TG
AUC for 10 weeks of age, 1 month on diet (14 weeks of age), and
4 months on diet (26 weeks of age) are shown in Fig. 3. In the
ASP(1/1) mice, there are progressive diet-induced increases in
TG AUC. In the ASP(2/2) mice there are also marked changes
in TG AUC that in most instances are larger than the wild
type. The differences in TG AUC between ASP(1/1) and
ASP(2/2) are not secondary to differences in basal TG levels,
since there is no change in fasting TG levels (Table I). At 1
month (low and high fat diet) and 4 months (low fat diet) the
TG AUC in ASP(2/2) is significantly increased compared with
ASP(1/1). At 4 months on the high fat diet, the TG AUC for
ASP(2/2) is reduced compared with HF ASP(1/1) but is still
significantly increased over the LF ASP(1/1) control.
The results for NEFA at 4 months are shown in Fig. 4 for low
fat (left panel) and high fat (right panel). In the wild type mice,
the increase in postprandial NEFA AUC is modest (20.6%
increase over basal AUC for LF and 30.8% for HF diet). By
contrast, the increase in NEFA in the ASP(2/2) mice is greater
than the (1/1) mice, 45% on LF and 70% on HF (p , 0.003 and
p , 0.0001, respectively, by two-way repeated measures
ANOVA).
We also examined glucose and insulin metabolism in the
mice. Fasting glucose and insulin are given in Table II. High fat
diets are recognized for their effects on inducing insulin resist-
ance and disordered glucose metabolism (28–30, 32–34). In the
ASP(1/1) mice, there is a slight increase in glucose with age,
as well as an effect of the high fat diet that increases glucose by
9% on average. There is a similar high fat effect on insulin that
increases by 2-fold at both 1 month and 4 months on the diet.
In the ASP(2/2) mice, there is a similar increase in insulin
with age and diet. However, the ASP(2/2) have significantly
lower glucose levels than the wild type at 14 and 26 weeks old
at any given insulin level, and this is evidenced by the reduced
insulinzglucose product, which is lower in the ASP(2/2) mice.
This relationship between insulin and glucose in ASP(1/1) and
FIG. 1. Postprandial lipemia in wild type (1/1) and ASP knock-
out (2/2) mice on low fat diet. An oral fat load was given to the mice
after 1 month on a low fat diet (14 weeks of age) and triglycerides (left
panel), and nonesterified fatty acids (right panel) were measured over
the 6-h time course for n 5 7 ASP(2/2) and n 5 8 ASP(1/1). Results
are shown as average 6 S.E. Two-way repeated measures of ANOVA
results indicate that there is a significant time (p , 0.02) and genotype
(p , 0.01) effect for triglyceride, but there is no significant change for
plasma nonesterified fatty acids.
FIG. 2. Postprandial lipemia in wild type (1/1) and ASP knock-
out (2/2) mice on high fat diet. An oral fat load was given to the mice
after 1 month on a high fat diet (14 weeks of age) and triglycerides (left
panel), and nonesterified fatty acids (right panel) were measured over
the 6-h time course for n 5 8 ASP(2/2) and n 5 10 ASP(1/1). Results
are given as average 6 S.E. Two-way repeated measures of ANOVA
results indicate that there is a significant time (p , 0.01) and genotype
(p , 0.04) effect for triglyceride and a significant genotype (p , 0.0003)
and time (p , 0.05) effect on plasma nonesterified fatty acids.
FIG. 3. Postprandial area under the curve (AUC) for triglycer-
ide and nonesterified fatty acids in wild type (1/1) and knock-
out (2/2) mice. An oral fat load was given to the mice at 10 weeks old
(basal), 14 weeks old (1 month (1 m) on LF or HF diet) and at 26 weeks
old (4 months (4 m) on LF or HF diet). Results are the average 6 S.E.
for 7 to 10 mice in each group (as indicated in Table III). Significance
was calculated by 2-way repeated measures of ANOVA using the indi-
vidual time points for all three treatment groups (wild type HF, knock-
out LF, and knockout HF) versus the control group (wild type LF),
where * represents p , 0.03, ** represents p , 0.003, and *** repre-
sents p , 0.0001.
FIG. 4. Postprandial nonesterified fatty acids in ASP(2/2) and
ASP(1/1) mice. An oral fat load was given to the mice after 4 months
on a low fat (left panel) or high fat (right panel) diet, and nonesterified
fatty acids were measured over the 6-h time course (ASP(2/2) n 5 7 LF
and 7 HF, and ASP(1/1) n 5 9 LF and 9 HF). Results are expressed as
average 6 S.E. where p , 0.003 (LF) and p , 0.0001 (HF) for ASP(2/2)
versus ASP(1/1) by 2-way repeated measures of ANOVA.
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ASP(2/2) was analyzed by linear regression analysis, and for
any given value of insulin, the corresponding glucose is signif-
icantly lower in the ASP(2/2) as compared with ASP(1/1) (p ,
0.002).
Postprandial glucose after a fat load at either 1 month or 4
months on LF or HF was no different in ASP(1/1) versus (2/2)
(Table III). In a subset of mice we also measured plasma
glucose after a glucose tolerance test (GTT) at 4.5 months on
LF or HF diet, and again there was no difference in ASP(1/1)
versus (2/2) (Table III). There was a clear effect of the high fat
diet in both wild type and knockout mice (Table III) where
glucose AUC increased 29 to 47% and was significant in all
cases. Finally, GTT insulin response increased with a high fat
diet in both ASP(1/1) and (2/2) but to a lesser extent in (2/2),
and on the LF diet only the insulin response to GTT was
significantly lower in ASP(2/2) versus ASP(1/1), p , 0.02.
We also looked at other factors related to energy nutrient
disposition and fat mass: growth curves of the mice, body
composition, leptin and food efficiency. The mice were weighed
each week from 4 to 26 weeks old, and the food intake moni-
tored over the dietary period (16 weeks from 10 to 26 weeks of
age). Although the knockout mice were slightly heavier at all
ages versus (1/1) by 9% 6 0.9% (LF) and 4.1% 6 0.3% (HF), the
differences were not significant. Total body weight on high fat
diets, relative to low fat diet, increased to the same extent in
both ASP(1/1) and ASP(2/2) by 22.5% 6 2.1% (1/1) and
18.7% 6 1.7% (2/2) over the 4-month period. Leptin, which
correlates very highly to body weight and adipose tissue mass,
was measured at several time points from 10 to 32 weeks of age
as an index of adiposity in the mice. Leptin increases both with
age and with diet in wild type mice, as reported by others (22,
23, 35), and this was also true of the ASP(2/2) mice. However,
as shown in Fig. 5, relative to body weight, there was always
significantly less leptin in ASP(2/2) versus (1/1), p , 0.006,
suggesting reduced whole body fat. This decrease in leptin was
reflected by small but significant decreases in adipose tissue
mass (Table IV) particularly in the gonadal and perirenal fat
(226% and 213% (LF), respectively), representing a decrease
from 6.3% ASP(1/1) to 4.2% ASP(2/2) fat versus body weight.
On the other hand, there was a significant increase in intras-
capular brown adipose tissue in the ASP(2/2) mice versus
ASP(1/1) on both the low and high fat diets (89 and 39%,
respectively, p , 0.05).
Finally, the ASP(2/2) mice appeared to be mildly hy-
perphagic, possibly as a result of decreased leptin levels. As
shown in Fig. 6, (low fat diet) there was little difference in
energy intake in ASP(1/1) versus (2/2) in the first 5 weeks
after the change to a low fat or high fat diet. However, after this
adjustment period the ASP(2/2) mice consistently consumed a
greater caloric load (112 6 1.8 ASP(2/2) versus 95.4 6 0.8
ASP(1/1) cal/week, a 17% increase for ASP(2/2) versus wild
type, p , 0.0001 by two way repeated measures ANOVA). This
was also true on the high fat diet (similar profiles), although to
a lesser extent, since all mice tended to increase their energy
intake on a high fat diet (average 131.4 6 3.8 ASP(2/2) versus
125.7 6 2.8 ASP(1/1) cal/week, a 6% increase for ASP(2/2)
versus wild type, p 5 0.07). When energy intake is calculated
relative to an increase in body weight (feed efficiency) over the
16-week period, the ASP(2/2) mice had a lower feed efficiency
(i.e. required more energy intake relative to body weight
gained) as compared with the ASP(1/1) on both the low fat diet
(148 6 19 ASP(2/2) versus 111 6 16 ASP(1/1) cal/g of body
weight gained, 33% increase, p , 0.001) and high fat diet
(109 6 18 ASP(2/2) versus 98.3 6 8 ASP(1/1) cal/g of body
weight gained, 11% increase, p 5 0.07).
DISCUSSION
In the present study we have examined in detail the ASP
knockout phenotype in male mice. These mice are character-
ized by 1) marked postprandial lipemia (triglycerides) and in-
creased postprandial nonesterified fatty acid levels on both low
and high fat diets, 2) increased energy intake/feed efficiency,
and 3) modest changes in insulin/glucose metabolism and lep-
tin/adiposity. On the other hand, in the female mice (reported
elsewhere), although the changes were directionally the same,
the female mice demonstrated greater changes in insulin/glu-
cose metabolism and leptin/adiposity, with smaller changes in
free fatty acids and, surprisingly, no postprandial lipemia. In
both types of mice, however, there were changes in energy
intake/feed efficiency.
Two characteristics of the ASP(2/2) male mice were (i) the
presence of marked postprandial lipemia in the ASP(2/2) mice
and (ii) increased energy intake/reduced feed efficiency. In-
creased postprandial lipemia as well as increased energy in-
take are also characteristic of wild type mice that have been
maintained on a high fat diet (24, 36). However, the similarities
between the ASP(2/2) phenotype and high fat diets in wild
type mice end there. Although the ASP(2/2) mice demonstrate
improved insulin/glucose, reduced leptin/adiposity, and in-
creased postprandial free fatty acids, wild type mice on a high
fat diet are characterized by increased glucose and insulin,
insulin resistance, increased leptin, increased adipose tissue
stores, and no dietary effect on free fatty acids. In fact, the
ASP(2/2) phenotype is maintained even when the mice are
placed on a high fat diet. The metabolic consequences (as dis-
cussed below) might be expected to be different between the
two phenotypes.
Postprandial triglycerides are cleared from the circulation in
TABLE II
Fasting glucose and insulin in ASP (2/2) and ASP (1/1) Mice
Fasting samples were obtained from ASP (2/2) and (1/1) mice at the indicated ages (sample size indicated for each group). Glucose z Insulin
represents the product of the two values. Values are expressed as average 6 S.E.
Mice Type Sample size Glucose Insulin Glucose z Insulin
mg/dl ng/ml
10 weeks (1/1) 5 112 6 15.8 0.32 6 0.08 27 6 5.5
(2/2) 11 99 6 14.0 0.31 6 0.03 28 6 4.7
14 weeks, LF (1/1) 8 113 6 12.7 0.20 6 0.06 43.4 6 16.8
(2/2) 7 91 6 3.9a 0.23 6 0.02 20.5 6 1.6
14 weeks, HF (1/1) 10 123 6 5.6 0.42 6 0.10 52.6 6 12.0
(2/2) 8 104 6 4.0b 0.51 6 0.11 46.3 6 10.0
26 weeks, LF (1/1) 9 126 6 9.1 0.42 6 0.08 56.1 6 13.9
(2/2) 10 104 6 5.8a 0.31 6 0.03 31.2 6 2.5a
26 weeks, HF (1/1) 10 136 6 8.9 0.84 6 0.12 111 6 13.2
(2/2) 7 117 6 10.3 0.91 6 0.20 78 6 11.6a
a p , 0.05 for (2/2) vs. (1/1).
b p , 0.025 for (2/2) vs. (1/1).
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a two-step coupled process. First, triglycerides are hydrolyzed
by the rate-limiting enzyme lipoprotein lipase (LPL), and sec-
ond, the free fatty acids generated are cleared from the circu-
lation by uptake into target tissues (white and brown adipose
tissue, muscle, and liver). Thus clearance of triglycerides will,
in the first instance, be regulated by the mass and activity of
LPL, which can be influenced genetically by mutation (37),
overexpression (38), or knockout of LPL (26). Environmentally,
the major influences on LPL are gender and the influence of sex
hormones (39), insulin levels and insulin sensitivity (40), and
inhibition by the local level of NEFA (41–43). On a high fat
diet, wild type (1/1) mice develop postprandial lipemia, prob-
ably due to reduced insulin sensitivity or its reduced effects on
LPL. On the other hand, in the male ASP(2/2) mice, the lack
of ASP results in increased circulating concentrations of NEFA
and delays in tissue free fatty acid uptake, and this may inhibit
LPL. As compared with the female mice, male wild type mice
have reduced adipose tissue mass (44), decreased LPL (45), and
increased insulin levels (46) and are more sensitive to high fat
diet-induced insulin resistance (31). These factors may com-
pound the effect of ASP deficiency, resulting in a pronounced
delay in postprandial TG clearance. Conversely, in the female
ASP(2/2) mice, the postprandial NEFA do not reach the same
levels as in the males, and there is no enhanced postprandial
lipemia. The most likely explanations are (i) increased adipose
tissue mass (relative to the males), which thus providing more
LPL and more tissue available for fatty acid uptake and ester-
ification, coupled to (ii) increased insulin sensitivity to stimu-
late LPL activity and fatty acid esterification. Thus alternate
mechanisms in female mice may help to compensate for the
lack of ASP.
We have previously demonstrated this same profile of post-
prandial lipemia (although to a lesser extent) in younger male
ASP(2/2) mice (19). By contrast, Wetsel et al. (47) have not
demonstrated a difference in postprandial triglycerides in their
study. In their study, they also did not find lower postprandial
triglycerides in female versus male mice, and their female mice
demonstrated higher apoB levels than males. The lack of sex-
ual dimorphism is unusual considering the well recognized
differences that have been reported elsewhere (24, 31, 45, 48)
and that we have also seen in both the ASP(1/1) and the
ASP(2/2) mice (19).
One explanation for the differences may lie in the colony
characteristics. Both colonies are a genetic hybrid of C57Bl/6
and 129Sv, and this genetic heterogeneity is controlled for in
both studies through the use of ASP(2/2) and (1/1) litter-
mates for the comparisons. However the relative contribution
of each background strain in our mice colony may be different
from theirs. We have back-crossed the ASP(2/2) onto each of
these two different strains to 98% genetic homogeneity (6-
generation back-cross). Not only are there strain differences in
the fasting lipids (as reported elsewhere (24, 49, 50) 2) and
postprandial profiles in the wild type, more notably there is
also differential expression of the ASP(2/2) phenotype, at least
as far as postprandial triglycerides are concerned.3 The differ-
ent insulin levels measured in these two mice strains may
account for these differences. This is consistent with different
insulin sensitivity between mouse strains, which may help to
compensate for the lack of ASP. In fact, strain-specific pheno-
typic expression of knockouts or naturally arising mutations
are not uncommon.
The association of increased postprandial NEFA, decreased
glucose relative to insulin, and decreased leptin/adiposity is
interesting with respect to the potential metabolic changes. In
the first instance, a decreased glucose-to-insulin ratio would
suggest increased insulin sensitivity in ASP(2/2) mice. This
increased insulin sensitivity coupled to the reduced leptin and
adipose tissue mass would provide a strong metabolic drive
toward increased energy intake and partitioning of calories to
the adipose tissue, leading to obesity. Thus it is even more
striking that, despite the slightly increased calorie-to-body
weight intake, even on a high fat diet, the ASP(2/2) mice are
not more obese than their (1/1) counterparts. This highlights
the important physiological function of ASP, which may be
necessary for efficient regulation of adipsoe tissue metabolism.
The increased postprandial NEFA coupled to the lower glu-
cose-to-insulin ratio suggests that there may also be changes in
nutrient partitioning. We would hypothesize that the de-
creased efficiency of NEFA uptake may result in enhanced
utilization of glucose, resulting in lowered plasma glucose lev-
els and greater insulin sensitivity. When delivery of NEFA to
tissues was disrupted by a targeted knockout of LPL, fasting
3 I. Murray, A. D. Sniderman, and K. Cianflone, manuscript in
preparation.
FIG. 5. Linear regression of leptin versus body weight in
ASP(2/2) and ASP(1/1) mice. Plasma leptin was measured in fast-
ing plasma from the age of 10 weeks to 48 weeks old on both low fat and
high fat diets and graphed versus body weight at the time of sampling.
Linear regression was calculated for ASP(1/1) versus ASP(2/2); the
two lines are significantly different at p , 0.006.
TABLE III
Postprandial and GTT, glucose and insulin AUC
Postprandial glucose over 6 h was measured at 14 weeks (1 month on diet) and 26 weeks (4 months on diet). Glucose and insulin were measured
following a 2-h GTT after 4.5 months on diet. In all cases, values are given for average AUC 6 S.E. and the % increase for HF vs. LF is indicated
(with significance).
Assay Type Sample size LF HF % Increase
Postprandial glucose (1 month) (1/1) (7/10) 649 6 57 875 6 62 35%, p , 0.0001
(2/2) (7/8 ) 632 6 67 857 6 79 32%, p , 0.0001
Postprandial glucose (4 months) (1/1) (9/9 ) 672 6 51 887 6 42 32%, p , 0.0001
(2/2) (7/7 ) 749 6 28 887 6 61 32%, p , 0.0001
GTT glucose (4.5 months) (1/1) (3/4 ) 287 6 36 423 6 34 47%, p , 0.0001
(2/2) (3/3 ) 330 6 10 371 6 34 29%, p , 0.001
GTT insulin (1/1) (3/4 ) 2.06 6 0.44 3.22 6 0.43 57%, p , 0.0001
(2/2) (3/2 ) 1.00 6 0.13a 2.91 6 0.49 90%, p , 0.001
a p , 0.02 for ASP (2/2) vs. ASP (1/1).
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plasma glucose was lower and even led to neonatal death (51).
Similarily, with GLUT 4 overexpression in mice, it was sug-
gested that the increased glucose uptake and storage into ad-
ipose tissue caused decreased NEFA adipose tissue uptake and
repartitioning of the available NEFA to muscle and brown
adipose tissue, resulting in increased NEFA oxidation (52).
This same process may be occurring in the ASP(2/2) mice. The
increase in brown adipose tissue mass would point in that
direction, and these issues are being explored presently.
In humans, there is considerable evidence suggesting that (i)
the association between obesity and glucose/insulin resistance/
diabetes as well as (ii) the association between obesity and
hyperlipidaemia/hyperapoB are mediated by alterations in
plasma NEFA and are collectively known as “syndrome X” (53).
Randle et al. (54) and more recently Bjorntorp (55) and Mc-
Garry (56) as well as others have proposed that the muscle
competition for NEFA/glucose utilization as well as NEFA ef-
fects on hepatic metabolism, reduced insulin removal, and in-
creased pancreatic insulin secretion are the cause of these
complications. These same authors have also documented the
link between NEFA and increased VLDL and apoB lipoprotein
secretion. In this scenario, any disturbance that increases
plasma NEFA would play a causative role, whether it be lack of
ASP, lack of response to ASP, or any other factor that disturbs
fatty acid metabolism, such as insulin resistance. We have
demonstrated increased postprandial NEFA (57) and abnormal
response to ASP (in cells) in such hyperapoB human subjects
(5, 58).
In mice, however, this cycle of obesity 3 NEFA 3 insulin
resistance/hyperlipidaemia does not appear to be present re-
gardless of whether the obesity is genetically or diet induced. In
our study, postprandial NEFA increases on either low or high
fat diet in ASP(2/2) mice were not associated with increased
glucose/insulin or fasting hyperlipidaemia. On the other hand,
the high fat diet, which was clearly associated with increased
plasma glucose, insulin, and to a lesser extent cholesterol was
not associated with any increase in fasting or postprandial
NEFA as compared with the low fat diet. This is true for both
ASP(1/1) as well as ASP(2/2). There are many other studies
that also demonstrate no change in plasma NEFA consequent
to high fat diet-induced obesity in wild type (1/1) and geneti-
cally obese mutant mice (30, 31, 33, 59–61), and this issue has
been discussed in a recent review (62). Although plasma cho-
lesterol may increase in mice on a high fat diet (28–31), there
is little change in plasma apoliporpotein B (31). In fact, in a
study with 10 different strains of mice (63) it was shown that
even in the presence of high fat and high cholesterol supple-
mentation, the effect on apoB was not significant (average 15%
6 7% increase), whereas the overall effect on plasma choles-
terol, VLDL CHOL, LDL CHOL, and HDL CHOL was highly
significant (37 to 103% increase, p , 0.001, calculated by the
author) (63). Thus the finding by Wetsel et al. (47) that
ASP(2/2) does not cause hyperapoB in mice is not unexpected.
We could not find any reports of NEFA-linked dietary/drug/
TABLE IV
Weight of adipose tissue depots in male mice at 8 months of age
Mice were fed the indicated diet from the age of 10 weeks and were sacrificed at 8 months of age. Results are expressed as average 6 S.E. %
bodyweight, and % decrease for (2/2) vs. (1/1). Each group has n 5 3, and significance level is indicated. BAT 5 intrascapular brown adipose
tissue.
Low fat diet High fat diet
g % Bodyweight g % Bodyweight
Inguinal
(1/1) 0.883 6 0.274 2.7% 2.559 6 0.047 6.1%
(2/2) 0.834 6 0.131 2.3% 2.642 6 0.142 6.2%
% decrease 26% 24%
Pectoral
(1/1) 0.758 6 0.136 2.4% 1.828 6 0.262 4.3%
(2/2) 0.711 6 0.142 2.0% 2.169 6 0.181 5.1%
% decrease 27% 118%
Gonadal
(1/1) 1.421 6 0.148 4.4% 2.699 6 0.120 6.4%
(2/2) 1.051 6 0.143 2.9% 2.378 6 0.199 5.6%
% decrease 226% p , 0.05 212%
Perirenal
(1/1) 0.574 6 0.093 1.8% 1.274 6 0.098 3.0%
(2/2) 0.501 6 0.097 1.4% 0.993 6 0.047 2.3%
% decrease 213% 222% p , 0.05
Sum peri-renal 1
gonadal
(1/1) 1.995 6 0.139 6.3% 3.973 6 0.194 9.4%
(2/2) 1.552 6 0.240 4.2% 3.372 6 0.161 7.9%
% decrease 213% 216% p , 0.05
BAT
(1/1) 0.294 6 0.050 0.9% 0.472 6 0.074 1.1%
(2/2) 0.556 6 0.089 1.5% 0.654 6 0.020 1.5%
% increase 189% p , 0.05 139% p , 0.05
FIG. 6. Food intake over time on a low fat diet. Food intake
(calories) was measured 2–3 times/week, and body weight was meas-
ured time/week on both ASP(1/1) (n 5 9) and ASP(2/2) (n 5 7) mice
from mice of 10 to 26 weeks old on a low fat diet. On average, the
ASP(2/2) mice consumed 16.5 6 2.1% more calories over the whole
time period versus the ASP(1/1), p , 0.0001 by 2-way repeated meas-
ures ANOVA.
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mutations that resulted in increased apoB hepatic production
in mice. Clearly, the normal metabolic responses to increased
NEFA in mice are very different from those in humans, and
this may lie in their capacity to increase thermogenesis and
oxidation, issues we are now pursuing in the ASP(2/2) mice.
In summary, these results demonstrate that ASP plays an
important role in adipose tissue metabolism, and lack of ASP
appears to alter both nutrient partitioning and the balance of
energy intake with body weight gain and adiposity. An ASP
antagonist could provide a pharmacologic target to alter adi-
pose tissue metabolism.
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